Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012

  • Email
  • Help

News

21/09/2012

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012

At the start of its September 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Tomas Salmonson as its new chair for a three-year mandate.

Dr Salmonson brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency (MPA). He has been a member of the CHMP for more than 12 years.

The opinions adopted by the CHMP at the September 2012 meeting and other important outcomes are listed in the table below.

The Agency publishes a new page following each month's CHMP meeting.

Positive recommendations on new medicines   

Name of medicineBindRen
International non-proprietary name (INN)colestilan
Marketing-authorisation applicantMitsubishi Pharma Europe Ltd.
Therapeutic indicationTreatment of hyperphosphataemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis
More informationSummary of opinion for BindRen

 

Name of medicineConstella
International non-proprietary name (INN)linaclotide
Marketing-authorisation applicantAlmirall, SA.
Therapeutic indicationTreatment of irritable bowel syndrome
More information

Summary of opinion for Constella


Press release: European Medicines Agency recommends authorisation of first medicine specifically for irritable bowel syndrome

 

Name of medicineEylea
International non-proprietary name (INN)aflibercept
Marketing-authorisation applicantBayer Pharma AG
Therapeutic indicationTreatment of neovascular (wet) age-related macular degeneration
More informationSummary of opinion for Eylea

 

Name of medicineNexoBrid
International non-proprietary name (INN)concentrate of proteolytic enzymes enriched in bromelain
Marketing-authorisation applicantTeva Pharma GmbH
Therapeutic indicationRemoval of eschar
More information

Summary of opinion for NexoBrid


Press release: European Medicines Agency recommends first medical treatment for removal of eschar from severe burn wounds

 

Name of medicinePicato
International non-proprietary name (INN)ingenol mebutate
Marketing-authorisation applicantLeo Pharma A/S
Therapeutic indicationTreatment of actinic keratosis
More informationSummary of opinion for Picato

 

Positive recommendation on a new informed-consent application

Name of medicineMemantine Merz
International non-proprietary name (INN)memantine
Marketing-authorisation applicantMerz Pharmaceuticals GmbH
Therapeutic indicationTreatment of Alzheimer's disease
More informationSummary of opinion for Memantine Merz

 

Positive recommendations on extensions of therapeutic indications 

Name of medicineEliquis
International non-proprietary name (INN)apixaban
Marketing-authorisation holderBristol-Myers Squibb / Pfizer EEIG
New therapeutic indicationThe CHMP adopted a new indication, prevention of stroke and systemic embolism in certain adult patients, and two new contraindications.
More informationSummary of opinion for Eliquis

 

Name of medicineAvastin
International non-proprietary name (INN)bevacizumab
Marketing-authorisation holderRoche Registration Ltd
New therapeutic indicationBevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelian ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular-endothelial-growth-factor (VEGF) inhibitors or VEGF receptor–targeted agents.
More informationSummary of opinion for Avastin

 

Name of medicineCialis
International non-proprietary name (INN)tadalafil
Marketing-authorisation holderEli Lilly Nederland B.V.
Therapeutic indication
(changes in bold)
Treatment of erectile dysfunction in adult males.
In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required.
Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.

Cialis is not indicated for use by women.
More informationSummary of opinion for Cialis

 

Name of medicineKomboglyze
International non-proprietary name (INN)saxagliptin / metformin hydrochloride
Marketing-authorisation holderBristol-Myers Squibb / AstraZeneca EEIG
Therapeutic indication
(changes in bold)
Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.
Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.
More informationSummary of opinion for Komboglyze

 

Name of medicineTrajenta
International non-proprietary name (INN)linagliptin
Marketing-authorisation holderBoehringer Ingelheim International GmbH
Therapeutic indication
(changes in bold)

Trajenta is indicated in the treatment of type-2 diabetes mellitus to improve glycaemic control in adults: 

  • as monotherapy:
    • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment;
  • as combination therapy:
    • in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;
    • in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;
    • in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
More informationSummary of opinion for Trajenta

 

Name of medicineViread
International non-proprietary name (INN)tenofovir disoproxil (as fumarate)
Marketing-authorisation holderGilead Sciences International Ltd
Therapeutic indicationPlease refer to the summary of opinion for all changes.
More informationSummary of opinion for Viread

 

Name of medicineVotubia
International non-proprietary name (INN)everolimus
Marketing-authorisation holderNovartis Europharm Ltd
Therapeutic indication
(changes in bold)

Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)

 

Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.


The evidence is based on analysis of change in sum of angiomyolipoma volume.


Subependymal giant cell astrocytoma (SEGA) associated with TSC.


Votubia is indicated for the treatment of patients aged 3 years and older with SEGA associated with TSC who require therapeutic intervention but are not amenable to surgery.


The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.

More informationSummary of opinion for Votubia

 

Name of medicineEucreas / Icandra / Zomarist
International non-proprietary name (INN)vildagliptin / metformin hydrochloride
Marketing-authorisation holderNovartis Europharm Ltd
Therapeutic indication
(changes in bold)

Vildagliptin / metformin hydrochloride is indicated in the treatment of type-2 diabetes mellitus:

  • in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets;
  • in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea;
  • in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
More information

Summary of opinion for Eucreas

Summary of opinion for Icandra

Summary of opinion for Zomarist

 

Name of medicineGalvus / Jalra / Xiliarx
International non-proprietary name (INN)vildagliptin
Marketing-authorisation holderNovartis Europharm Ltd
Therapeutic indication
(changes in bold)

Vildagliptin is indicated in the treatment of type-2 diabetes mellitus in adults:

  • as monotherapy:
    • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;
  • as dual oral therapy in combination with:
    • metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
    • a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance;
    • a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate;
  • as triple oral therapy in combination with:
    • a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.

Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

More information

Summary of opinion for Galvus

Summary of opinion for Jalra

Summary of opinion for Xiliarx

 

Positive recommendation on a new contraindication

Name of medicineMultaq
International non-proprietary name (INN)dronedarone
Marketing-authorisation holderSanofi
Contraindications
(changes in bold)
  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
  • Second- or third-degree atrioventricular block, complete bundle branch block, distal block, sinus node dysfunction, atrial conduction defects, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker).
  • Bradycardia <50 beats per minute (bpm).
  • Permanent atrial fibrillation (AF) with an AF duration ≥6 months (or duration unknown) and attempts to restore sinus rhythm no longer considered by the physician.
  • Patients in unstable haemodynamic conditions.
  • History of or current heart failure or left ventricular systolic dysfunction.
  • Patients with liver and lung toxicity related to the previous use of amiodarone.
  • Co-administration with potent cytochrome P450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir.
  • Medicinal products inducing torsades de pointes such as phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides (such as erythromycin), class I and III antiarrhythmics.
  • QTc Bazett interval ≥500 milliseconds.
  • Severe hepatic impairment.
  • Severe renal impairment (CrCl <30 ml/min).
  • Co-administration with dabigatran
More informationSummary of opinion for Multaq

 

Positive recommendations on new generic medicines

Name of medicineCapecitabine Medac
International non-proprietary name (INN)capecitabine
Marketing-authorisation applicantMedac Gesellschaft für klinische Spezialpräparate mbH
Therapeutic indicationTreatment of colon cancer
More informationSummary of opinion for Capecitabine Medac

 

Name of medicineIbandronic acid Accord
International non-proprietary name (INN)ibandronic acid
Marketing-authorisation applicantAccord Healthcare Limited
Therapeutic indicationPrevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases, and treatment of tumour-induced hypercalcaemia with or without metastases.
More informationSummary of opinion for Ibandronic acid Accord

 

Name of medicineZoledronic Acid Hospira
International non-proprietary name (INN)zoledronic acid
Marketing-authorisation applicantHospira UK Ltd
Therapeutic indicationPrevention of skeletal related events and treatment of tumour-induced hypercalcaemia
More informationSummary of opinion for Zoledronic Acid Hospira


Opinion on safety issue

Medicines studied at Texas-based Cetero Research facility


Other updates

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures
Opinions on safety variations
Start of Community reviews
Scientific advice and protocol assistance
Guidelines and concept papers adopted during the September 2012 CHMP meeting
Overview of invented names reviewed in September 2012 by the Name Review Group (NRG)
Organisational matters

How useful is this page?

Average rating:

 Based on 38 ratings

Add your rating:

See all ratings
10 ratings
2 ratings
2 ratings
3 ratings
21 ratings

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore users are asked to check the page regularly.